<DOC>
	<DOCNO>NCT01963598</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multicenter phase 2 study safety efficacy 3-month subcutaneous ( SC ) REGN1033 ( SAR391786 ) treatment patient sarcopenia .</brief_summary>
	<brief_title>Study Safety Efficacy REGN1033 ( SAR391786 ) Patients With Sarcopenia</brief_title>
	<detailed_description />
	<mesh_term>Sarcopenia</mesh_term>
	<criteria>1 . Men woman age 70 year old ( woman participate study must postmenopausal ) 2 . Are capable , investigator 's opinion , complete study per protocol significant health issue condition 3 . Ability follow walk program 4 . Willing able comply clinic visit studyrelated procedure 5 . Provide sign informed consent 6 . Able understand complete studyrelated questionnaire 1 . Hospitalization immobilization duration &gt; 48 hour within month prior screen 2 . Surgical procedure require general anesthesia within 1 month prior screening , plan surgical procedure require general anesthesia within next 6 month 3 . Participate resistance training 3 time per week regular exercise consist average 30 minute per day least moderate physical activity 4 . Chronic medication introduce within 2 week prior screen 5 . Respiratory disease require oxygen treatment 6 . Cancer require treatment currently past 3 year ( except primary nonmelanoma skin cancer situ cervical cancer ) 7 . Neurological condition cause impaired muscle function mobility 8 . Certain cardiovascular condition 9 . Uncontrolled diabetes The information list intend contain consideration relevant patient 's potential participation clinical trial inclusion/ exclusion criterion list .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>